Nesina Act Tablet 25/30 mg
Alogliptin Benzoate 34mg · Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication · Combination
Celltrion Healthcare Co., Ltd.
MFDS item code 201404897 · Approved 2014.10.24
This product's status changed to Approval withdrawn on 2024.12.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes further improve their blood sugar control in conjunction with dietary and exercise therapy. It effectively manages blood sugar levels through the combined administration of alogliptin and pioglitazone, helping to prevent complications of diabetes. Therefore, it is used effectively for blood sugar control in patients with type 2 diabetes.
This medicine is administered once daily, with or without food. Do not split the tablets. The recommended starting doses of this medicine (alogliptin/pioglitazone) are as follows. ● For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy: Administer this medicine 25mg/15mg. ● For patients who do not achieve adequate glycemic control with metformin monotherapy: Administer this medicine 25mg/15mg. ● For patients who do not achieve adequate glycemic control with pioglitazone monotherapy: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● For patients who do not achieve adequate glycemic control with combination therapy of pioglitazone and metformin: Administer this medicine 25mg/15mg or 25mg/30mg, depending on the current treatment regimen. ● Replacement of combination therapy with alogliptin and pioglitazone: When switching from combination therapy with alogliptin and pioglitazone to this medicine, start at the current doses of alogliptin and pioglitazone. This medicine may be increased to a maximum of 25mg/30mg once daily according to the glycemic response. When starting treatment with this medicine or increasing the dose, closely monitor the patient for adverse reactions associated with fluid retention observed with pioglitazone use (e.g., weight gain, edema, and signs and symptoms of congestive heart failure). Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50 mL/min): No dose adjustment is required. - Patients with moderate renal impairment (creatinine clearance ≥30~ <50 mL/min): Administer this medicine 12.5 mg/15 mg or 12.5 mg/30 mg once daily. - This medicine should not be administered to patients with severe renal impairment or end-stage renal disease. - Because dose adjustment may be necessary depending on renal function, assessment of renal function is recommended before starting treatment with this medicine and periodically thereafter.
This medication may put strain on the heart in some patients, potentially worsening or newly causing heart failure. Therefore, after starting or increasing the dosage of this medication, careful observation of symptoms of heart failure such as weight changes, shortness of breath, and swelling is necessary. Patients with heart failure or a history of heart failure should not take this medication and should immediately consult a doctor if symptoms occur. Moreover, this medication may cause fluid retention leading to edema, which may be associated with heart failure, so caution is needed. This medication should not be administered to patients with certain genetic diseases or severely impaired liver or kidney function, patients with bladder cancer, pregnant women, or women who may become pregnant. During administration, if there are any bladder-related symptoms such as hematuria or urinary disorders, patients should inform their doctor immediately. This medication can cause hypoglycemia, so caution should be exercised for symptoms of hypoglycemia when used in combination with glucose-lowering agents like insulin or sulfonylureas, and dosage adjustment may be necessary. Additionally, this medication may affect liver function, so liver function tests should be performed prior to administration, and if any abnormal liver function symptoms develop during usage, immediate consultation with medical personnel is required. For premenopausal women, this medication may induce ovulation and increase the risk of pregnancy, so proper contraception is recommended. If severe joint pain or blistering skin conditions occur while taking this medication, it must be reported to a doctor immediately and treated. The elderly, patients with deteriorating kidney function, those who consume excessive alcohol, and patients with poor nutritional status should use this medication with caution. Lastly, the safety and efficacy of this medication for children have not been established, and it is advisable for breastfeeding women to avoid its use.
Congestive heart failure, excessive and rapid weight changes, shortness of breath, edema, fluid retention, serious adverse reactions including congestive heart failure, gross hematuria, urinary disorders, urgency, nasopharyngitis, back pain, upper respiratory infections, influenza, hypoglycemia, headache, sinusitis, myalgia, pharyngitis, pancreatitis, hypersensitivity reactions, serum sickness, elevated serum creatine kinase, diabetic macular edema accompanied by visual impairment, fatal and non-fatal liver failure, weight gain, edema, hemoglobin decrease, fractures, bladder cancer, visual impairment, macular edema, severe and disabling arthralgia, vesicular pemphigoid, anaphylaxis, angioedema, rash, urticaria, Stevens-Johnson syndrome, pemphigoid, acute pancreatitis, bowel obstruction, interstitial nephritis, hematological changes, thrombocytopenia, bleeding, coagulopathy, abscesses, infections, wound defects, chest discomfort, generalized edema, general weakness, cirrhosis, cholelithiasis, acute renal failure, nephrolithiasis, renal dysfunction, myocardial infarction, angina pectoris, anorexia, cerebral infarction, transient ischemic attack, speech disorders, tendonitis, fractures, costochondritis, leg fractures, upper limb fractures, spinal fractures, rhabdomyolysis, tendon rupture, pruritus, contact dermatitis, itching, keratosis, sclerosis, increased sweating, nail disorders, otitis externa, pityriasis rosea, rosacea, contact dermatitis, furunculosis, seborrheic dermatitis, cystitis, renal dysfunction, exacerbated cystitis, increased urinary frequency, neurogenic bladder, renal cysts, urethritis, hematuria, elevated blood creatinine levels, conjunctivitis, glaucoma, macular degeneration, cataracts, keratitis, retinal diseases, retinal disorders, retinal diseases, diabetic retinopathy, retinal diseases, cholelithiasis, unspecified liver function test abnormalities, cirrhosis, biliary sclerosis, fatty liver, increased AST, increased ALT, herpes zoster, depression, hyperactivity, erectile dysfunction, insomnia, sleep disorders, benign prostatic hyperplasia, benign prostatic hyperplasia, orthostatic hypotension, hypotension, tinnitus, acute hearing loss, Meniere's disease, unspecified ear disease, coronary artery obstruction, myocardial infarction, angina pectoris, exacerbation of angina pectoris, bradycardia, palpitations, exacerbation of atrial fibrillation, palpitations, atherosclerosis, hypothyroidism, nodular thyroid disease, diarrhea, dyspepsia, constipation, gastritis, exacerbation of gastritis, nausea, malaise, vomiting, cough, sputum disorders, bronchitis, nasopharyngitis, rhinorrhea, pneumonia, shortness of breath, chest pain, back pain, ineffective response, chest discomfort, pelvic pain, leg edema, exacerbated back pain, weakness, sacral pain, low back pain, pain, arm swelling, exacerbated chest pain, fever, fatigue, sacral pain
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is best to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature. Storing it this way will help to safely preserve the efficacy of the medication.
Pink, biconvex round film-coated tablet
28 tablets (7 tablets/PTP x 4), 100 tablets (10 tablets/PTP x 10)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Alogliptin Benzoate 34mg · Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication · Combination
Celltrion Healthcare Co., Ltd.
Alogliptin Benzoate 34mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Alogliptin Benzoate 17mg · Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication · Combination
Celltrion Pharma Co., Ltd.
Alogliptin Benzoate 17mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationAlogliptin Benzoate 34mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationAlogliptin Benzoate 34mg · Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.